Products with Anti-sepsis bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2541 | Tanshinone IIA-sulfonic sodium |
| Tanshinone IIA sulfonate (sodium) is a water-soluble derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.Sodium tanshinone IIA sulfonate pretreatment reduces infarct size and improves cardiac function in an ischemia-reperfusion-induced rat myocardial injury model via activation of Akt/FOXO3A/Bim-mediated signal pathway. | |
| BCN3836 | Kukoamine B |
| 1. Kukoamine B is a potent dual inhibitor for both Lipopolysaccharides (LPS) and oligodeoxynucleotides containing CpG motifs (CpG DNA), LPS and CpG DNA are important pathogenic molecules for the induction of sepsis,are drug targets for sepsis treatment, thus kukoamine B is worthy of further investigation as a potential candidate to treat sepsis. 2. Kukoamine B inhibits inflammation in septic mice by reducing the concentrations of plasma LPS, decreasing leukocyte sequestration and interfering with NFκB activation, and, therefore, suppressing the proadhesive phenotype of endothelial cells. 3. Kukoamine B has protective effects against hydrogen peroxide (H2O2) induced cell injury and potential mechanisms in SH-SY5Y cells, it may potentially serve as an agent for prevention of several human neurodegenerative and other disorders caused by oxidative stress. | |
| BCN5899 | Senegenin |
| Senegenin has anti-apoptotic,anti-oxidative,and neuroprotective activities, it might be a potential agent for prevention and treatment of postoperative cognitive dysfunction (POCD) or other neurodegenerative diseases. It also be a potential therapeutic agent against sepsis. Senegenin decreased the levels of TNF-α ,IL-1β, NF-κB. | |
| BCN6287 | Ruscogenin |
| Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities.Ruscogenin significantly attenuates LPS-induced acute lung injury (ALI )via inhibiting expressions of TF and iNOS and NF-κB p65 activation, it inhibits activation of neutrophil through cPLA 2 , PAK, Akt, MAPKs, cAMP, and PKA signaling pathways. | |
